Literature DB >> 29110121

[Nanoparticles as drug delivery systems in ophthalmology].

M Löscher1, J Hurst1, L Strudel1, M S Spitzer1,2, S Schnichels3.   

Abstract

Nanoparticles are perfectly suited as drug delivery systems due to their size and the diversity of materials used. They are able to penetrate biological barriers, can directly deliver drugs to the target site and provide a sustained release profile. Having long been established in oncology, in the last decade research has started to take a closer look at the potential of nanoparticles for ocular drug delivery. Obstacles, such as poor delivery of drugs via eye drops and the side effects of invasive methods, such as placing implants as drug depots could be overcome. Among the most relevant investigated structures are polymeric nanoparticles, micelles, liposomes, solid lipid nanoparticles, dendrimers and cyclodextrins. Besides the composition of the nanoparticle itself, its efficacy and stability can be optimized through coatings; however, long-term stability, standardization of production and toxicity remain the major challenges. The preclinical and partly clinical results obtained so far will hopefully give impulse to the idea of applying nanoparticles for optimized ocular drug delivery in the near future.

Entities:  

Keywords:  Active substance uptake; Biocompatibility; Drug uptake; Targeted delivery; Toxicity

Mesh:

Substances:

Year:  2018        PMID: 29110121     DOI: 10.1007/s00347-017-0596-6

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  30 in total

1.  Model of transient drug diffusion across cornea.

Authors:  Wensheng Zhang; Mark R Prausnitz; Aurélie Edwards
Journal:  J Control Release       Date:  2004-09-30       Impact factor: 9.776

2.  Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration.

Authors:  Hu Yang; Puneet Tyagi; Rajendra S Kadam; Christopher A Holden; Uday B Kompella
Journal:  ACS Nano       Date:  2012-08-21       Impact factor: 15.881

Review 3.  The cost offsets and cost-effectiveness associated with pegylated drugs: a review of the literature.

Authors:  Russell Becker; Carole Dembek; Leigh Ann White; Louis P Garrison
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2012-12       Impact factor: 2.217

4.  Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin.

Authors:  Chandrasekar Durairaj; Rajendra S Kadam; John W Chandler; Stephen L Hutcherson; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-19       Impact factor: 4.799

Review 5.  Nanoparticle-based technologies for retinal gene therapy.

Authors:  Jeffrey Adijanto; Muna I Naash
Journal:  Eur J Pharm Biopharm       Date:  2015-01-12       Impact factor: 5.571

6.  Topical dexamethasone γ-cyclodextrin nanoparticle eye drops increase visual acuity and decrease macular thickness in diabetic macular oedema.

Authors:  Akihiro Ohira; Katsunori Hara; Gauti Jóhannesson; Masaki Tanito; Gudrún Marta Ásgrímsdóttir; Sigrún H Lund; Thorsteinn Loftsson; Einar Stefánsson
Journal:  Acta Ophthalmol       Date:  2015-07-23       Impact factor: 3.761

7.  Treatment of experimental autoimmune uveoretinitis with intravitreal injection of tacrolimus (FK506) encapsulated in liposomes.

Authors:  Rui Zhang; Rong He; Jiang Qian; Jie Guo; Kang Xue; Yi-Fei Yuan
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-02-17       Impact factor: 4.799

8.  Cyclosporine a-loaded solid lipid nanoparticles: ocular tolerance and in vivo drug release in rabbit eyes.

Authors:  Evren H Gökçe; Giuseppina Sandri; Sait Eğrilmez; M Cristina Bonferoni; Tamer Güneri; Carla Caramella
Journal:  Curr Eye Res       Date:  2009-11       Impact factor: 2.424

9.  Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment.

Authors:  Mohammed M Mehanna; Hoda A Elmaradny; Magda W Samaha
Journal:  Drug Dev Ind Pharm       Date:  2010-01       Impact factor: 3.225

Review 10.  Nanopharmaceuticals (part 1): products on the market.

Authors:  Volkmar Weissig; Tracy K Pettinger; Nicole Murdock
Journal:  Int J Nanomedicine       Date:  2014-09-15
View more
  4 in total

1.  Hyaluronan-Loaded Liposomal Dexamethasone-Diclofenac Nanoparticles for Local Osteoarthritis Treatment.

Authors:  Ming-Cheng Chang; Ping-Fang Chiang; Yu-Jen Kuo; Cheng-Liang Peng; Kuan-Yin Chen; Ying-Cheng Chiang
Journal:  Int J Mol Sci       Date:  2021-01-11       Impact factor: 5.923

2.  Fabrication and Characterization of Tedizolid Phosphate Nanocrystals for Topical Ocular Application: Improved Solubilization and In Vitro Drug Release.

Authors:  Mohd Abul Kalam; Muzaffar Iqbal; Abdullah Alshememry; Musaed Alkholief; Aws Alshamsan
Journal:  Pharmaceutics       Date:  2022-06-23       Impact factor: 6.525

3.  Perspectives of Positively Charged Nanocrystals of Tedizolid Phosphate as a Topical Ocular Application in Rabbits.

Authors:  Abdullah Alshememry; Musaed Alkholief; Mohd Abul Kalam; Mohammad Raish; Raisuddin Ali; Sulaiman S Alhudaithi; Muzaffar Iqbal; Aws Alshamsan
Journal:  Molecules       Date:  2022-07-20       Impact factor: 4.927

Review 4.  Topical Drug Delivery to the Posterior Segment of the Eye.

Authors:  Marina Löscher; Chiara Seiz; José Hurst; Sven Schnichels
Journal:  Pharmaceutics       Date:  2022-01-06       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.